Business Wire

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Del

Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD’s innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this platform for the development of novel therapeutics in collaboration with nanoPET Pharma GmbH, a former shareholder of ICD Therapeutics. Further details of the acquisition are not being disclosed.

“Boehringer Ingelheim’s collaboration with nanoPET Pharma has the potential to eliminate the hurdle that many cancer biologics face: getting access to targets inside tumor cells,” said Norbert Kraut, Ph.D., Global Head of Cancer Research, Boehringer Ingelheim. “We will use ICD’s MacroDel technology to develop first-in-class potential drug candidates for intracellular targets across a variety of tumor types, for the benefit of patients who so far have no or only inadequate treatment options.”

Engineered proteins and peptides offer great potential to block protein-protein interactions inside cancer cells, but their large size is generally assumed to prevent intracellular delivery. ICD’s MacroDel technology exploits transporter proteins in the cell membrane to deliver such drug candidates inside tumor cells. This opens up therapeutic targets that would be otherwise inaccessible.

“nanoPET Pharma looks forward to collaborating with Boehringer Ingelheim on the pre-clinical refinement of ICD’s MacroDel to achieve effective intracellular delivery of macromolecules such as peptides and proteins,” said Andreas Briel, Ph.D., Managing Director of nanoPET Pharma GmbH. “We are excited to contribute to Boehringer Ingelheim’s discovery and development of innovative medicines for patients in need.”

More about MacroDel
Tree-like highly branched molecules known as dendrimers form a fundamental component of the MacroDel platform. The size, shape and electrical charge of this structure permit it to grasp large therapeutic biological molecules. After binding with the biologic, the resulting compound selectively interacts with transporter proteins known to be highly expressed on tumor cell wall membranes. These transporters help “carry” the compound through the membrane and into the cell. The medicinal cargo is then in position to disrupt the disease process in a precise manner at a molecular level.

A prior investment from Boehringer Ingelheim’s Venture Fund (BIVF) supported ICD’s development of the MacroDel technology. The BIVF strategically invests in groundbreaking therapeutics-focused biotechnology companies to enable development of their technologies for therapeutic applications that have potential for strategic partnerships with Boehringer Ingelheim or other pharmaceutical partners.

Please click on the link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/acquisition-novel-oncology-delivery-technology

Contact information

Media Contacts:
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com

nanoPET Pharma GmbH
Dr. Andreas Briel
nanoPET Pharma GmbH
Robert-Koch-Platz 4
D-10115 Berlin
Tel. +49 (0)30 890 49 740
Email: andreas.briel@nanopet.de

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AnyVision Closes $74 Million Series A with New Participation from M12 and DFJ Growth18.6.2019 11:10:00 CESTPressemelding

AnyVision, a leading computer vision company specializing in face, body, and object-recognition software, today announced the close of its $74 million Series A financing round. New investment comes from M12, Microsoft’s venture fund, DFJ Growth and OG Technology Partners. As part of the Series A, AnyVision previously announced investment from LightSpeed Venture Partners, Robert Bosch GmbH, Qualcomm Ventures, and Eldridge Industries. AnyVision, founded in 2015, is a leading computer vision company specializing in face, body, and object-recognition software. AnyVision develops core software solutions that make all cameras smart. These solutions are agnostic to all cameras, computing frameworks, and use-cases. “There are very few times in business when you have the opportunity to build an entirely new industry alongside leading ecosystem players,” said Eylon Etshtein, CEO and Co-Founder of AnyVision. “We are fortunate to have the backing of chipmakers like Qualcomm, camera manufacturers s

IDEMIA Launches Augmented Vision, its Next Generation Video Analytics Application at IFSEC International18.6.2019 11:07:00 CESTPressemelding

IDEMIA, the global leader in Augmented Identity, launches its video analytics application enhancing security in public and private places. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005513/en/ Credits: IDEMIA Augmented Vision supports security officers in identifying persons of interest in real-time, and helps speed up post-event investigations. This latest cutting-edge technology from IDEMIA will enhance security in transport hubs (airports, stations…), stadiums and arenas, retail and commercial buildings, as well as gaming and entertainment sites that face growing security challenges. The application is based on IDEMIA’s long-standing expertise in deep learning and biometrics for video and image analysis including IDEMIA’s facial recognition technology: a longstanding best-in-class combination of efficiency, scalability and accuracy for facial recognition as evidenced by IDEMIA’s leading position in the most rece

F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA18.6.2019 11:00:00 CESTPressemelding

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer. Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody therapeutics in oncology. Previously, Darlene held CFO positions across both private and publicly listed US companies, including Pieris Pharmaceuticals Inc., Microline Surgical Inc. and T2 Biosystems Inc. She brings to F-star a proven track record of finance strategy and leadership, capital raising, industry knowledge and the ability to build strong strategic partnerships. Darlene Deptula-Hicks, CFO of F-star, said: “It is a very exciting time to be joining F-star given its evolution to a f

Norsk Titanium Receives Airbus Contract for Qualification and Production18.6.2019 10:00:00 CESTPressemelding

Officials with Norsk Titanium (Norsk) announce today a contract award from Airbus for the Qualification and Serial Production of the first parts to be manufactured utilizing wire-based Direct Energy Deposition (DED) additive manufacturing technology. “We have worked closely with Airbus over several years to demonstrate the technological maturity and the industrial readiness of our Rapid Plasma Deposition™ (RPD™) process,” said Norsk President and CEO Michael Canario. “This contract award is structured to enable long-term, serial production immediately following qualification. Our Plattsburgh, New York facility, with the assistance of Airbus technical leadership, has been preparing for this moment and is eager to demonstrate a 21st century advanced additive manufacturing capability.” This qualification of Airbus parts will demonstrate the suitability of the DED additive manufacturing process for aircraft structural parts. It will formalize the process by which individual parts are produ

Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients18.6.2019 10:00:00 CESTPressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System. The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs. Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FD

Innovusion Announces Its High-Resolution Image-Grade LiDAR System “Cheetah”, Enabling the Safest Performance in the Vehicle Mobility Industry18.6.2019 09:00:00 CESTPressemelding

Innovusion Inc., the worldwide leader in the design and development of innovative hybrid Solid State LiDAR systems for vehicle safety applications, has announced the availability of its Cheetah system. Based on its innovative rotating polygon optical architecture, Innovusion has melded together proprietary detector electronics, advanced optics and sophisticated software algorithms to offer a system that has no equal in the long-distance, high-resolution LiDAR vehicle mobility system industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190618005066/en/ Innovusion's Cheetah long-distance LiDAR System...the safest in the mobility safety industry (Graphic: Business Wire) Smart architecture, streamlined optics design, and integrated optical paths result in rapid manufacturing, scalability into automotive production, and lower cost. The ability to provide a detection range of 200 meters on objects with 10% reflectivity and cle